Bosun Hau’s Post

AstraZeneca’s Imfinzi Combination Shows Promise in Hepatocellular Carcinoma Treatment AstraZeneca's immunotherapy drug, Imfinzi, in combination with transarterial chemoembolization (TACE) and bevacizumab, has shown significant progress in treating hepatocellular carcinoma (HCC), a form of liver cancer. The EMERALD-1 Phase III trial found that Imfinzi, when used alongside TACE, led to a meaningful improvement in progression-free survival (PFS) compared to TACE alone in eligible HCC patients. The trial involved 616 patients from 18 countries, and the primary endpoint of PFS showed promising results. The trial is also examining the secondary endpoint of overall survival (OS). The researchers believe that this combination therapy has the potential to reshape the treatment landscape for HCC and improve outcomes for eligible patients. AstraZeneca plans to discuss these findings with regulatory authorities, and the safety profiles of the medications used were consistent with previous knowledge. The positive results suggest that Imfinzi-based treatments may offer new hope for patients with earlier stages of liver cancer. AstraZeneca's ongoing clinical development program for Imfinzi also includes investigations in various gastrointestinal cancer settings. For more details please click the link! https://lnkd.in/duW44HPU #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

The combination of sintilimab and axitinib demonstrated safety and initial efficacy in patients with fumarate hydratase-deficient renal cell carcinoma. https://lnkd.in/e4bru94g

Another milestone not only for solid tumors and #allogeneic #NK #celltherapy, but also for cryopreserved starting material! The #cryopreservation process allows to maintain significant cellular cytotoxicity, and potentially making hundreds of thousands of #NKcell doses from a single donor. Learn how CPC Services can help your #clinicaltrial patient sample processing and cryopreservation and storage of starting material. www.cpcservices.com https://lnkd.in/eSPurzXs #immunotherapy #cancerresearch #clinicalresearch

Yesterday, FDA granted regular approval for pralsetinib - a RET-specific tyrosine kinase inhibitor - for patients with metastatic RET-rearranged non-small cell #lungcancer (#NSCLC). This #drug has been available since 2020, when it received "accelerated approval." The #acceleratedapproval pathway allows faster approval of #drugs for serious or life-threatening #illnesses based on surrogate endpoints that are reasonably likely to predict #clinical benefit. Confirmatory studies lead to full approval or, less commonly, withdrawal of approval for the indication. For pralsetinib, the initial approval was based on based on overall response rate and duration of response in 114 #patients. Conversion to full approval followed data from 123 more patients and an additional 25 months of follow-up, showing durability of the previously demonstrated response. The same trial supported post-approval confirmatory studies, which is usually the most efficient bridge to full approval. @RogerDKlein RogerDKlein.com #cancer #oncology #regulation https://lnkd.in/gtEAC-gY

#LEAP001 #keytruda #Phase3 #failure #endometrialcancer #1L #merck  --Phase 3 LEAP-001 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, did not meet its dual primary endpoints of overall survival (OS) and progression-free survival (PFS) for the first-line treatment of patients with advanced or recurrent endometrial carcinoma whose disease is mismatch repair proficient (pMMR)/not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)/MSI-H. https://lnkd.in/gyy-9Zc8

Usually if a patient has HNSCC and upto metastatic stage, that is hard enough for oncologist to deal with. Even more desperate if the patient is with PD-L1 level less than 1%, in which case anti-PD1 drugs are not meant to be beneficial. Then if that patient is not suitable to take chemotherapy, practically, out of option so far. However, things are about to change from now on, because of this small peptide, Eftilagimod Alpha, from Immutep!

Head and Neck Squamous Cell Carcinoma (HNSCC) Market Gearing Up for Outstanding Expansion During the Forecast Period (2023-32) | Merck, Eli Lilly, Bristol‑Myers Squibb, Sanofi-Aventis, Sinocelltech: Delveinsight Business Research LLP As per DelveInsight, the Head and Neck Squamous Cell Carcinoma Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Head and Neck Squamous Cell Carcinoma, … Continue reading → #Finance #FinancialMarket #MarketingSales #PharmaceuticalsBiotech

Always hard to make conclusions off press releases.  But it appears as though pembrolizumab/lenvatinib did not show improvement over carboplatin/paclitaxel in first-line pMMR/MSS advanced or recurrent endometrial carcinoma.  These patients were platinum sensitive, and we do know that platinum-based therapy is effacacious in this patient population.  Pembrolizumab plus carboplatin and paclitaxel showed a trend towards benefit in this pMMR patients in NRG-GY018, so it's unlikely that pembrolizumab is the reason this trial did not read out positively.  Lenvatinib is not cytotoxic chemotherapy, and this trial shows that there is still a role for cytotoxic chemotherapy in upfront therapy.  While immunotherapy plus TKI may have a synergistic effect, this effect does not appears to be greater than that of traditional cytotoxic chemotherapy, at least in this patient population. #endometrialcancer #keytruda #lenvima https://lnkd.in/g_7fpZvD